Date: 2016-06-24
Type of information: Private placement
Company: Global Blood Therapeutics (USA - CA)
Investors:
Amount: $112.3 million
Funding type: private placement
Planned used:
Others: * On June 24, 2016, Global Blood Therapeutics announced the closing of its previously announced underwritten public offering of 6,400,000 shares of common stock, at the public offering price of $18.75 per share. All of the shares in the offering were offered by GBT. GBT estimates net proceeds from the offering to be approximately $112.3 million, after deducting underwriting discounts and commissions and estimated offering expenses. * On June 20, 2016, Global Blood Therapeutics announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock at a public offering price of $18.75 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional 960,000 shares of common stock on the same terms and conditions. The offering is expected to close on or about June 24, 2016, subject to the satisfaction of customary closing conditions. * On June 20, 2016, Global Blood Therapeutics announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All shares of common stock will be offered by GBT. In addition, GBT expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of common stock at the public offering price, less the underwriting discount. J.P. Morgan Securities LLC and Morgan Stanley are acting as joint book-running managers for the offering. Cowen and Company, LLC and Wedbush PacGrow are acting as co-managers. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
